Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Dassault Systemes lifts 2021 outlook on surging software sales

07/27/2021 | 02:22am EDT
FILE PHOTO: French software company Dassault Systemes hikes its 2021 forecasts on July 27, 2021

(Reuters) - French software company Dassault Systemes on Tuesday hiked its 2021 forecasts on the back of strong momentum across its activities, including in its industrial systems and life sciences businesses.

The group, which makes 3D design software and technologies for manufacturing, infrastructure and healthcare groups, now expects non-IFRS revenue growth of 10%-11% this year, bringing its earnings per share to up to 0.91 euros ($1.07), adjusting for the company's five-for-one stock split earlier this month.

It had previously said it expects revenue growth of up to 10% and EPS of up to 0.86 euros. It also predicted further year-on-year growth for the current quarter.

The company noted strong contributions from its transport and mobility software as well as its life sciences business, which helps to manage clinical trials.

Its software was used in around 400 trials related to COVID-19 treatments and vaccines for some 200 companies, finance chief Pascal Daloz told reporters in a call - including those developed by Novavax, Moderna and AstraZeneca.

"Today the challenge is the variants," he said, adding that the company was using modelling and simulation to predict mutations and help develop vaccines that are effective against the most dominant strain.

Daloz said he expected that these companies would continue to use Dassault Systemes after the pandemic to conduct trials virtually from patients' homes instead of in hospitals.

For the April-June period, the group's non-IFRS earnings per share jumped 35% to 0.22 euros from revenues up 8% to 1.16 billion euros - a touch above analysts' estimates.

($1 = 0.8477 euros)

(Reporting by Sarah Morland in Gdansk, Editing by Sherry Jacob-Phillips and Louise Heavens)

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -1.07% 8617 Delayed Quote.18.92%
DASSAULT SYSTÈMES SE -1.39% 50.23 Real-time Quote.53.30%
MODERNA, INC. 1.54% 440.72 Delayed Quote.315.47%
NOVAVAX, INC. 0.75% 232.01 Delayed Quote.106.52%
All news about ASTRAZENECA PLC
09:45aASTRAZENECA : Anger, confusion spread over UK's new COVID travel rules
07:20aPFIZER : COVID-19 Vaccine Elicits Strong Immune Response As Second Dose, Thailand Study Sa..
04:32aSINOVAC BIOTECH : Thailand delays plan to re-open cities to tourists until November
04:27aIndia's Serum Institute to invest $68 mln in UK vaccine maker Oxford Biomedica
04:03aASTRAZENECA : MEDIA-UK govt approves Covishield as qualified vaccine for travel - Mint
02:25aOXFORD BIOMEDICA : Swings to H1 Profit on Revenue from COVID-19 Vaccine Manufacturing
01:57aASTRAZENECA : India likely to allow smaller gap between AstraZeneca COVID vaccine doses so..
09/21Shangula Rages Against West's Vaccine Nationalism
09/21ASTRAZENECA : India calls new UK COVID-19 vaccine rules 'discriminatory'
09/21ASTRAZENECA : Investment will transform development and commercialisation of new medicines..
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 401 M - -
Net income 2021 5 006 M - -
Net Debt 2021 24 250 M - -
P/E ratio 2021 24,1x
Yield 2021 3,27%
Capitalization 133 B 182 B -
EV / Sales 2021 4,46x
EV / Sales 2022 3,59x
Nbr of Employees 76 100
Free-Float 96,3%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Last Close Price 86,17 $
Average target price 136,24 $
Spread / Average Target 58,1%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC18.92%184 103
JOHNSON & JOHNSON4.16%433 122
ROCHE HOLDING AG9.82%321 584
PFIZER, INC.20.08%246 246
NOVO NORDISK A/S52.07%234 070